Smaller dogs are known to have an increased risk of chemotherapy‐induced myelosuppression for doxorubicin, mitoxantrone and melphalan. This retrospective study aimed to determine if dogs <15 kg and <10 kg experienced greater degrees of myelosuppression following treatment with carboplatin chemotherapy compared with dogs ≥15 kg. One hundred and one dogs treated with carboplatin for a variety of malignancies were retrospectively analysed. Eight dogs (61%) weighing <10 kg, three (38%) weighing 10 kg to <15 kg and 14 (17%) weighing ≥15 kg experienced a grade 3 or 4 neutropenia. Five dogs (38%) weighing <10 kg, two (25%) weighing 10 kg to <15 kg and 13 (16%) weighing ≥15 kg experienced a grade 3 or 4 thrombocytopenia. Dogs <10 kg were significantly more likely to develop a grade 3 or 4 neutropenia following carboplatin than dogs ≥10 kg (3.5 RR; 95% CI, 1.9‐6.3; P < .001). Dogs <15 kg were also significantly more likely to develop a grade 3 or 4 neutropenia than dogs ≥15 kg (3 RR; 95% CI, 1.6‐5.6; P = .004). Dogs <10 kg were significantly more likely to develop a grade 3 or 4 thrombocytopenia than those dogs ≥10 kg (2.5 RR; 95% CI, 1.1‐5.6; P = .006). Hospitalization was significantly more likely for dogs <10 kg vs ≥10 kg (P = .014) as well as for dogs <15 kg vs ≥15 kg (P = .039). This study demonstrates an increased risk of carboplatin‐induced myelosuppression in dogs <15 kg, and particularly those <10 kg. This information should be considered by clinicians when making decisions regarding the initial carboplatin dose for smaller canine patients, especially those <15 kg.

中文翻译：

---

卡铂诱导的骨髓抑制与狗的体重有关。

已知较小的狗因化疗引起的多柔比星、米托蒽醌和美法仑骨髓抑制的风险增加。这项回顾性研究旨在确定与体重≥15 kg 的狗相比，<15 kg 和 <10 kg 的狗在接受卡铂化疗后是否经历了更大程度的骨髓抑制。对 101 只接受卡铂治疗各种恶性肿瘤的狗进行了回顾性分析。八只 (61%) 体重 <10 公斤，三只 (38%) 体重 10 公斤至 <15 公斤，14 只 (17%) 体重≥15 公斤，出现 3 级或 4 级中性粒细胞减少症。五只 (38%) 体重 <10 公斤，两只 (25%) 体重 10 公斤至 <15 公斤，13 只 (16%) 体重≥15 公斤，出现 3 或 4 级血小板减少症。狗 <P  < .001)。与体重 ≥ 15 kg 的狗相比，<15 kg 的狗也更容易出现 3 或 4 级中性粒细胞减少症（3 RR；95% CI，1.6-5.6；P = .004）。与体重 ≥ 10 kg 的狗相比，<10 kg 的狗发生 3 或 4 级血小板减少症的可能性显着更高（2.5 RR；95% CI，1.1-5.6；P = .006 ）。住院显著更可能对狗<10公斤VS≥10公斤（P = 0.014），以及狗<15公斤VS≥15公斤（P = 0.039）。该研究表明，<15 kg 的狗，尤其是 <10 kg 的狗，卡铂诱导的骨髓抑制的风险增加。临床医生在为体型较小的犬科动物（尤其是 <15 kg 的犬科动物）决定初始卡铂剂量时应考虑这些信息。